Mast cell–derived plasminogen activator inhibitor type 1 promotes airway inflammation and remodeling in a murine model of asthma - 04/07/18
Supported by American Heart Association grant 11SDG7590063 and National Institutes of Health grant 1K23AI110731. This material is the result of work supported with resources and the use of facilities at the James A. Haley Veterans' Hospital. The contents do not represent the views of the Department of Veterans Affairs or the United States Government. |
|
Disclosure of potential conflict of interest: R. P. Schleimer has received grants from the National Institutes of Health (NIH); has consultant arrangements with Intersect ENT, GlaxoSmithKline, Allakos, Aurasense, Merck, BioMarck, Sanofi, AstraZeneca/MedImmune, Genentech, Exicure, and Otsuka; and has stock/stock options in Allakos, Aurasense, BioMarck, and Exicure. S. H. Cho has received grants from the American Heart Association, the NIH, and Sanofi and has received personal fees from Sanofi. The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 142 - N° 1
P. 294 - juillet 2018 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?